Ramer Robert, Wendt Franziska, Wittig Felix, Schäfer Mirijam, Boeckmann Lars, Emmert Steffen, Hinz Burkhard
Institute of Pharmacology and Toxicology, Rostock University Medical Centre, 18057 Rostock, Germany.
Clinic and Polyclinic for Dermatology and Venereology, Rostock University Medical Centre, 18057 Rostock, Germany.
Cancers (Basel). 2022 Mar 31;14(7):1769. doi: 10.3390/cancers14071769.
Drugs targeting the endocannabinoid system are of interest as potential systemic chemotherapeutic treatments and for palliative care in cancer. In this context, cannabinoid compounds have been successfully tested as a systemic therapeutic option in preclinical models over the past decades. Recent findings have suggested an essential function of the endocannabinoid system in the homeostasis of various skin functions and indicated that cannabinoids could also be considered for the treatment and prophylaxis of tumour diseases of the skin. Cannabinoids have been shown to exert their anticarcinogenic effects at different levels of skin cancer progression, such as inhibition of tumour growth, proliferation, invasion and angiogenesis, as well as inducing apoptosis and autophagy. This review provides an insight into the current literature on cannabinoid compounds as potential pharmaceuticals for the treatment of melanoma and squamous cell carcinoma.
靶向内源性大麻素系统的药物作为潜在的全身化疗治疗手段以及癌症姑息治疗药物备受关注。在此背景下，在过去几十年中，大麻素化合物已在临床前模型中成功作为一种全身治疗选择进行了测试。最近的研究结果表明，内源性大麻素系统在各种皮肤功能的稳态中具有重要作用，并表明大麻素也可考虑用于皮肤肿瘤疾病的治疗和预防。大麻素已被证明在皮肤癌进展的不同阶段发挥抗癌作用，如抑制肿瘤生长、增殖、侵袭和血管生成，以及诱导细胞凋亡和自噬。本综述深入探讨了关于大麻素化合物作为治疗黑色素瘤和鳞状细胞癌潜在药物的当前文献。
